Moneycontrol PRO
Upcoming Event:Attend Quants League - 5 Days Live Algorithmic Options Trading Virtual Conference @ just Rs. 600/- brought to you by Moneycontrol Pro. Register Now!
you are here: HomeNewsBusiness

Cadila's Ahmedabad plant completes USFDA inspection with no observations

The United States Food and Drug Administration (USFDA) inspected the company's topical manufacturing facility in Ahmedabad during December 16-20, 2019, the drug firm said in a BSE filing.

December 20, 2019 / 04:53 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cadila Healthcare on Friday said it has not received any observation from the US health regulator after the inspection of its Ahmedabad manufacturing facility.

The United States Food and Drug Administration (USFDA) inspected the company's topical manufacturing facility in Ahmedabad during December 16-20, 2019, the drug firm said in a BSE filing.

"At the end of the inspection, no observation (483) is issued ," it added.

As per the USFDA, an FDA Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.

It notifies the company's management of objectionable conditions at the inspected facility.

Close
Shares of Cadila Healthcare were trading at Rs 266.30 per scrip on the BSE, up 1.82 percent from its previous close.
PTI
first published: Dec 20, 2019 03:07 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark